logo

Beam Therapeutics Inc. (BEAM)



Trade BEAM now with
  Date
  Headline
8/9/2022 6:41:11 AM Beam Therapeutics Q2 Net Loss $72.0 Mln Or $1.02/Shr Vs Loss Of $76.3 Mln Or $1.23/Shr Last Year
8/1/2022 4:46:22 PM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $100 Price Target
8/1/2022 6:41:29 AM Beam Therapeutics Announces FDA Clinical Hold On BEAM-201 IND Application
5/9/2022 7:04:41 AM Beam Therapeutics Q1 Net Loss $69.2 Mln Or $1.01/Shr Vs Loss $201.6 Mln Or $3.35/Shr Last Year
2/28/2022 5:03:42 PM Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) FY22 Estimate To -6.29 From -3.71
2/28/2022 5:03:19 PM Wedbush Is Lowering Beam Therapeutics Inc. (BEAM) Q4 22 Estimate To -1.63 From -0.96
2/28/2022 5:03:00 PM Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) Q3 22 Estimate To -1.59 From -0.94
2/28/2022 5:02:43 PM Wedbush Is Cutting Beam Therapeutics Inc. (BEAM) Q2 22 Estimate To -1.55 From -0.91
2/28/2022 5:02:32 PM Wedbush Is Lowering Beam Therapeutics Inc. (BEAM) Q1 22 Estimate To -1.53 From -0.91
2/28/2022 5:00:27 PM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $152 Down From $159 Price Target
1/10/2022 6:05:13 AM Pfizer And Beam Therapeutics Enter Research Collaboration To Advance Novel In Vivo Base Editing Programs
10/19/2021 4:21:40 PM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $148 Price Target
9/28/2021 7:13:43 AM Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $148 Price Target
8/10/2021 9:11:51 AM Beam Therapeutics Q2 Loss Attributable To Stockholders $76.3 Mln Or $1.23/Shr Vs Loss $34.2 Mln Or $0.69/Shr Last Year
6/28/2021 9:55:54 AM Beam Therapeutics Gains 16%
3/15/2021 7:00:37 AM Beam Therapeutics Q4 Net Loss Attributable To Common Stockholders $95.5 Mln Or $1.69 Per Share